Can This High-Yield Dividend Stock Keep Beating the S&P 500? [Yahoo! Finance]
Amgen Inc. (AMGN)
Last amgen inc. earnings: 4/30 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investors.amgen.com
Company Research
Source: Yahoo! Finance
Amgen (NASDAQ: AMGN) , a top-tier U.S. biotech firm, has been a coveted dividend stock since it began regular distributions to shareholders in 2011. Highlighting this fact, the company's shares have significantly outperformed the S&P 500 during this time. Can Amgen's stock continue to deliver excess returns relative to this benchmark index? Let's delve into the drugmaker's core value proposition to find out. Amgen: A reversal of fortune Amgen's shares have gotten off to a rocky start in 2024. Since the start of the year, the biotech's stock price has fallen by a hefty 8% compared to a nearly 7% gain for the S&P 500. Amgen's stock has come under pressure following a bull run in 2023. Investors bid up the biotech's stock by almost 10% last year in response to the excitement over its experimental weight loss candidate, MariTide. Early-stage data suggest MariTide might sport a dosing advantage over competing drugs in the category and, perhaps, a superior safety profile as well.
Show less
Read more
Impact Snapshot
Event Time:
AMGN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AMGN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AMGN alerts
High impacting Amgen Inc. news events
Weekly update
A roundup of the hottest topics
AMGN
News
- Sandoz reaches agreement with Amgen over patent dispute [Reuters]Reuters
- Hydronephrosis Treatment Market Size to Surpass US$4.31 Billion by 2033, The Brainy Insights [Yahoo! Finance]Yahoo! Finance
- AMGEN ANNOUNCES WEBCAST OF 2024 FIRST QUARTER FINANCIAL RESULTSPR Newswire
- What's in the Cards for Amgen (AMGN) This Earnings Season? [Yahoo! Finance]Yahoo! Finance
- AMGEN TO SUBMIT TEPROTUMUMAB MARKETING AUTHORIZATION APPLICATION TO THE EUROPEAN MEDICINES AGENCY [Yahoo! Finance]Yahoo! Finance
AMGN
Earnings
- 2/6/24 - Beat
AMGN
Sec Filings
- 4/26/24 - Form DEFA14A
- 4/17/24 - Form DEFA14A
- 4/17/24 - Form DEF
- AMGN's page on the SEC website